Cytosorbents Corporation reported its financial results for the third quarter of 2025, revealing a total revenue of $9.5 million, a 10.1% increase from $8.6 million in the same period last year. For the nine months ending September 30, 2025, the company generated $27.8 million in revenue, up 5.2% from $26.4 million in the prior year. The gross profit for the quarter was approximately $6.7 million, reflecting a gross margin of 70.3%, compared to 61.0% in the previous year. The company’s loss from operations improved to $2.9 million, down from $4.8 million in the third quarter of 2024, indicating a 40.7% reduction in operational losses.
The financial performance was bolstered by a strategic reorganization of the company's sales approach, particularly in Germany, which is expected to enhance future revenue generation. Operating expenses for the third quarter decreased to $9.5 million from $10.1 million year-over-year, driven by reduced research and development costs, which fell by nearly 50% due to the completion of clinical trials. However, selling, general, and administrative expenses saw a slight increase, attributed to costs related to regulatory submissions for the upcoming DrugSorb-ATR product.
In terms of operational developments, Cytosorbents has made significant strides in expanding its product offerings and market presence. The company is actively pursuing FDA approval for its DrugSorb-ATR device, which aims to address perioperative bleeding in high-risk surgeries. The anticipated regulatory decision is expected in mid-2026. Additionally, the company has strengthened its balance sheet through a rights offering that raised $5.4 million in net proceeds and the exercise of warrants that added another $1.4 million.
As of September 30, 2025, Cytosorbents reported total assets of $45.8 million, with cash and cash equivalents amounting to approximately $9.1 million. The company has also initiated a strategic workforce and cost reduction plan, which includes a 10% reduction in workforce aimed at optimizing operations and accelerating a path to cash-flow profitability. Despite these efforts, the company expressed concerns about its ability to continue as a going concern within the next twelve months, highlighting the need for additional capital to support ongoing operations and product development.
Looking ahead, Cytosorbents remains focused on expanding its customer base and enhancing its product offerings. The company is exploring various financing options, including equity offerings and debt financing, to secure the necessary capital for its growth initiatives. The management is optimistic about achieving cash flow breakeven by the first quarter of 2026, contingent on the successful execution of its strategic plans and regulatory approvals.
About Cytosorbents Corp
CytoSorbents Corporation specializes in blood purification technologies for critical care, cardiac surgery, and organ transplantation. Its flagship product, CytoSorb, removes inflammatory mediators, toxins, and blood thinners from blood using porous polymer beads. The company develops and markets extracorporeal cartridges and devices globally, targeting high-risk patients with conditions like sepsis, COVID-19, organ failure, and bleeding risks, with a focus on improving clinical outcomes and reducing healthcare costs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.